GlaxoSmithKline Merger Completion Delayed To Year-End
This article was originally published in The Tan Sheet
Executive Summary
The planned merger of SmithKline Beecham and Glaxo Wellcome will be delayed, likely until the end of the year, due to continued Federal Trade Commission inquiries.
You may also be interested in...
NiQuitin CQ Smoking Cessation Lozenge Could Be On U.S. Shelves By Year-End
GlaxoSmithKline has submitted an NDA for its NiQuitin CQ lozenges and could receive FDA approval before the end of the year, the firm said
Glaxo Zantac 75 Divestiture To W-L Required By FTC
Glaxo Wellcome has agreed to sell trademark rights and other controls over the marketing of OTC Zantac 75 to Warner-Lambert Consumer Group in order to complete its merger with SmithKline Beecham in accordance with a proposed consent order issued by the Federal Trade Commission Dec. 18.
SmithKline Aquafresh 3Q Growth Offsets Smoking Cessation Sales Slip
A 2% increase in SmithKline Beecham's oral care product sales worldwide, propelled by 9% growth in the Aquafresh line, helped the firm's consumer healthcare division maintain level third quarter sales, SB announced Oct. 31.